nintedanib
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Anika Sharma
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...
